47
Participants
Start Date
November 23, 2020
Primary Completion Date
August 31, 2023
Study Completion Date
April 24, 2024
NNC0361-0041
Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
Placebo
Placebo
The Naomi Berrie Diabetes Center at Columbia University Medical Center, New York
University of Pittsburgh, Pittsburgh
Emory Children's Center, Atlanta
University of Florida, Gainesville
Vanderbilt Eskind Diabetes Center, Nashville
Indiana University - Riley Hospital for Children, Indianapolis
Regents of the University of Minnesota, Minneapolis
The Children's Mercy Hospital, Kansas City
University of Texas Southwestern Medical Center, Dallas
Barbara Davis Center at University of Colorado Anschutz Medical Campus, Aurora
Children's Hospital of Orange County, Orange
University of California - San Francisco, San Francisco
Stanford University, Stanford
Benaroya Research Institute, Seattle
Yale University School of Medicine, New Haven
Joslin Diabetes Center, Boston
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH